Clinical Trials Using Cabazitaxel

Clinical trials are research studies that involve people. The clinical trials on this list are studying Cabazitaxel. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 1-7 of 7
  • Abiraterone Acetate and Antiandrogen Therapy with or without Cabazitaxel and Prednisone in Treating Patients with Metastatic, Castration-Resistant Prostate Cancer Previously Treated with Docetaxel

    This randomized phase II trial studies how well abiraterone acetate and antiandrogen therapy, with or without cabazitaxel and prednisone, work in treating patients with castration-resistant prostate cancer previously treated with docetaxel that has spread to other parts of the body. Androgens can cause the growth of prostate cancer cells. Hormone therapy using abiraterone acetate and antiandrogen therapy may fight prostate cancer by lowering and / or blocking the use of androgens by the tumor cells. Drugs used in chemotherapy, such as cabazitaxel and prednisone, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving abiraterone acetate and antiandrogen therapy with or without cabazitaxel and prednisone may help kill more tumor cells.
    Location: 615 locations

  • Study of Nivolumab Plus Ipilimumab, Ipilimumab or Cabazitaxel in Men With Metastatic Castration-Resistant Prostate Cancer

    The purpose of this study is to determine whether Nivolumab plus Ipilimumab has preliminary evidence of safety and effectiveness in the treatment of participants with metastatic castration-resistant prostate cancer who have progressed after prior Docetaxel-containing regimen.
    Location: 4 locations

  • Enzalutamide and Cabazitaxel in Treating Patients with Metastatic, Castration-Resistant Prostate Cancer

    This phase I / II trial studies the side effects and best dose of cabazitaxel when given together with enzalutamide in treating patients with prostate cancer that has spread to other places in the body (metastatic) and has not responded to treatment with hormones or no longer responds to treatment with hormones (hormone-resistant). Drugs used in chemotherapy, such as cabazitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Androgen can cause the growth of prostate cancer cells. Hormone therapy using enzalutamide may fight prostate cancer by blocking the use of androgen by the tumor cells. Giving cabazitaxel together with enzalutamide may work better in treating metastatic, hormone-resistant prostate cancer.
    Location: 3 locations

  • Rapid Cycle Combination Therapy in Treating Patients with Metastatic Castrate-Resistant Prostate Cancer

    This phase II trial studies how well rapid cycle combination therapy works in treating patients with prostate cancer that has not responded to surgery or hormone therapy and has spread to other places in the body. Androgen can cause the growth of tumor cells. Antihormone therapy, such as abiraterone acetate and enzalutamide, may lessen the amount of androgen made by the body. Drugs used in the chemotherapy, such as radium Ra 223 dichloride, cabazitaxel, and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Switching between different combinations of androgen deprivation therapy and chemotherapy after a short time may prevent drug resistance and help achieve better long-term control of prostate cancer.
    Location: 2 locations

  • Carboplatin, Cabazitaxel and Abiraterone in Treating Patients with Metastatic Castration Sensitive Prostate Cancer

    This phase II trial studies how well carboplatin, cabazitaxel and abiraterone work in treating patients with prostate cancer that has spread to other areas of the body (metastatic), but is still responding to hormone therapy (castration sensitive). Drugs used in chemotherapy, such as carboplatin and cabazitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Abiraterone may block tissues from making androgens (male hormones), which may cause the death of tumor cells that need androgens to grow. Giving carboplatin, cabazitaxel and abiraterone may improve cancer control.
    Location: University of Minnesota / Masonic Cancer Center, Minneapolis, Minnesota

  • Olaparib, Cabazitaxel, Carboplatin, and Prednisone in Treating Patients with Metastatic Prostate Cancer

    This phase II trial studies how well olaparib, cabazitaxel, carboplatin, and prednisone work in treating patients with prostate cancer that has spread to other places in the body. Olaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as cabazitaxel, carboplatin, and prednisone, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving olaparib, cabazitaxel, carboplatin, and prednisone may work better in treating patients with prostate cancer.
    Location: M D Anderson Cancer Center, Houston, Texas

  • Prednisone, Abiraterone, Cabazitaxel, and Enzalutamide in Treating Patients with Metastatic Castration-Resistant Prostate Cancer

    This phase I trial studies the side effects and best dose of cabazitaxel when given together with prednisone, abiraterone, and enzalutamide in treating patients with castration-resistant prostate cancer that has spread to other places in the body. Prednisone is an orally given steroid drug that helps in blocking some side effects of abiraterone. Abiraterone may lower the level of testosterone and enzalutamide may block the action of testosterone and these actions will prevent the growth of prostate cancer. Drugs used in chemotherapy, such as cabazitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving prednisone, abiraterone, cabazitaxel, and enzalutamide may work better in treating patients with castration-resistant cancer.
    Location: University of Alabama at Birmingham Cancer Center, Birmingham, Alabama